Prognostic Value of KRAS/TP53/PIK3CA in Non‑small Cell Lung Cancer

Oncology Letters - Greece
doi 10.3892/ol.2019.10012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

P2.01-44 Prognostic Value of TP53 Hot Exon Mutation in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

PIK3CA Mutations Frequently Coexist With EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

PLoS ONE
Multidisciplinary
2014English

K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value

ISRN Molecular Biology
2012English

Outcome Analysis of Phase I Trial Patients With Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non–Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P3.16-24 Prognostic Value of Positive Lymph Node Ratio in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Prognostic Significance of CD276 in Non-Small Cell Lung Cancer

Open Medicine (Poland)
Medicine
2019English

Prognostic Gene Signatures for Non-Small-Cell Lung Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy